| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that an abstract with final results of CORE-001, its Phase 2 trial of cretostimogene in combination with pembrolizumab, will be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, which will take place from May 31-June 4, 2024, at McCormick Place Convention Center, in Chicago, IL.
"We are delighted to be sharing the final results from our CORE-001 Phase 2 trial at ASCO, in line with the guidance we previously gave of providing additional CORE-001 durability data in 1H 2024," said Vijay Kasturi, M.D., Chief Medical Officer, CG Oncology. "In anticipation of sharing the final results from this trial, we would like to extend our heartfelt thanks to the investigators and patients who contributed to the trial's success."
Details of the abstract are as follows:
Final results of CORE-001 trial of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in Patients with BCG-Unresponsive, Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
Abstract Number: 4601
Session & Primary Track: Poster Session, Genitourinary Cancer - Kidney and Bladder
Presenter: Roger Li, M.D., lead study investigator and Urologic Oncologist at Moffitt Cancer Center
Presentation Date & Time: June 2, 2024, 9:00-10:00am Central Daylight Time
Location: McCormick Place Convention Center, Hall A
Posted In: CGON
